Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial

American Journal of Psychiatry

Volumn 175, Issue 3, 2018, Pages 225-231

  McGuire, Philip ^a   Robson, Philip ^a   Cubala, Wieslaw Jerzy ^a   Vasile, Daniel ^a   Morrison, Paul Dugald ^a   Barron, Rachel ^a   Taylor, Adam ^a   Wright, Stephen ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; OLANZAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; COGNITION; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; FEMALE;

ADULT; ANTIPSYCHOTIC AGENTS; CANNABIDIOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 85041139213     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17030325     Document Type: Article

References (23)

1. Miyamoto S, Duncan GE, Marx CE, et al: Treatments for schizophrenia: a critical review of pharmacology and mechanismsofaction of antipsychotic drugs. Mol Psychiatry 2005;10:79-104
2. Stone JM, Raffin M, Morrison P, et al: Review: the biological basis of antipsychotic response in schizophrenia. J Psychopharmacol 2010;24:953-964
3. Demjaha A, Egerton A, Murray RM, et al: Antipsychotic treatment resistanceinschizophreniaassociatedwithelevatedglutamate levels but normal dopamine function. Biol Psychiatry 2014;75:e11-e13
4. Fusar-Poli P, Papanastasiou E, Stahl D, et al: Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebocontrolled trials. Schizophr Bull 2015;41:892-899
5. Englund A, Freeman T, Murray R, et al: Can wemake cannabis safer? Lancet Psychiatry 2017;4:643-648
6. Morrison PD, Murray RM, Kapur S: In healthy subjects cannabidiol inhibits delta-9-tetrahydrocannabinol induced acute psychosis and tachycardia via a non-pharmacokinetic mechanism. J Psychopharmacol 2010;24:A61
7. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al: Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010;35:764-774
8. Zuardi AW, Shirakawa I, Finkelfarb E, et al: Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-250
9. Leweke FM, Schneider U, Radwan M, et al: Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000;66:175-181
10. Englund A, Morrison PD, Nottage J, et al: Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19-27
11. Miyamoto S, Miyake N, Jarskog LF, et al: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012;17:1206-1227
12. Zuardi AW, Morais SL, Guimarães FS, et al: Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-486
13. Zuardi AW, Crippa JA, Hallak JE, et al: Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009;23:979-983
14. Leweke FM, Piomelli D, Pahlisch F, et al: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94
15. Leucht S: Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 2014;75(suppl 1):8-14
16. Hallak JE, Machado-de-Sousa JP, Crippa JA, et al: Performance of schizophrenic patients in the Stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010;32:56-61
17. Martin-Santos R, Crippa JA, Batalla A, et al: Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012;18:4966-4979
18. Zuardi AW, Crippa JA, Hallak JE, et al: A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 2012;18:5131-5140
19. Zuardi AW, Hallak JE, Dursun SM, et al: Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20:683-686
20. Crippa JA, Derenusson GN, Ferrari TB, et al: Neuralbasisofanxiolytic effects of cannabidiol (CBD) ingeneralizedsocial anxietydisorder: a preliminary report. J Psychopharmacol 2011;25:121-130
21. Ventriglio A, Gentile A, Stella E, et al: Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015;9:297
22. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS: Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3364-78
23. Seeman P: Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 2016;6:e920